Funded by a $230,979 grant, an Ohio University study tests metformin to prevent Clostridioides difficile in heart patients.
A critical problem in treating Clostridioides difficile infections is the possibility that the pathogen develops resistance ...
High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides ...
Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted ...
Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile - commonly known as C. diff - are a serious and persistent problem for patients and ...
Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...
STATEN ISLAND, N.Y., March 9, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results